Analytical Chemist submits:
Newly profitable small-cap biotechnology company DUSA Pharmaceuticals (DUSA) is an investment with fantastic return opportunities. With rapidly increasing sales and its greater than 80% gross margin leading to even more rapidly growing profits, investors may want to join in the chant: D-U-S-A! D-U-S-A! DUSA is an integrated dermatological biotechnology company whose main products treat the common skin condition actinic keratoses (AK), precancerous lesions caused by sun exposure. AKs are responsible for more than 8 million visit to dermatologists and other skin care physicians annually. This figure is significantly higher than 2003’s 5.2 million visits. It is estimated that the direct costs of AK are greater than $1 billion annually.
Levulan PDT is used to treat non-hyperkeratoic AK of the face or scalp. AKs are precancerous lesions caused by sun exposure. Levulan PDT is applied with DUSA’s Kerastick. Exposure to DUSA’s BLU-U light source converts the application into the drug actually